{"name":"Insight Molecular Diagnostics","slug":"insight-molecular-diagnostics","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":4055000,"revenueGrowth":115.6,"grossMargin":0,"rdSpend":15900000,"netIncome":-50222000,"cash":25756000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2029-01-31","label":"Adjuvant Phase 3 readout (Stage IB-IIIA Non-small Cell Lung Carcinoma)","drug":"Adjuvant","drugSlug":"adjuvant","type":"phase3_readout","sentiment":"neutral"},{"date":"2031-05-01","label":"Adjuvant Phase 3 readout (Invasive Breast Cancer, Stage III Breast Cancer)","drug":"Adjuvant","drugSlug":"adjuvant","type":"phase3_readout","sentiment":"neutral"},{"date":"2034-10-02","label":"Adjuvant Phase 3 readout (Breast Cancer)","drug":"Adjuvant","drugSlug":"adjuvant","type":"phase3_readout","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Adjuvant","genericName":"Adjuvant","slug":"adjuvant","indication":"Other","status":"discontinued"}]}],"pipeline":[{"name":"Adjuvant","genericName":"Adjuvant","slug":"adjuvant","phase":"discontinued","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxOZEtKemFsQmd3eEd6aVJtN0lwbVN1YWttR2VxenE0YzlTX0NtVk1tM3MxeGRCX09ralhndzhEUHQ2dlpxMUtlem5lRjhzeDM5NkRQZzU2Z09UbzBjWVl2aXJpckRkZmxyOXhqbGhUbjNkdDRUMEpOSTNMV1VzODZfTXQwbnByQlBFV3RYaHV0b28xNm15bDdpSVE4YkRDUUl2MEh0SjNfdENHbzAydDlGMzVyU2dOZw?oc=5","date":"2026-03-31","type":"pipeline","source":"Benzinga","summary":"12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga","headline":"12 Health Care Stocks Moving In Tuesday's Pre-Market Session","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxOUG9LcTJUTTJZSkVYVVl2bnVCNHdWZ0l2N1ZhTlE3ZjYzSk1ZeXo4Q0VjV1NPNzVuQVprUDFFRWRuTUsyYXJEakhPRFoteDhMTVM3SlhxTjdleFdkRW5xbEZqckpRRWJOUEd4T2dzdTVhRlc5ZHl1WjRlT2VveDYxYnNyYTlGS3ZKVEtLc0pJbDRpMFpSNWlBVHhzLVFMVWc2TGNPZ19kWTQ1Rk9hVFZwbmxRZXd3b3EwMjRUVQ?oc=5","date":"2026-03-26","type":"pipeline","source":"Stock Titan","summary":"[10-K] Insight Molecular Diagnostics Inc. Files Annual Report - Stock Titan","headline":"[10-K] Insight Molecular Diagnostics Inc. Files Annual Report","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxPdGFtYWlnUGkxRWRkWm1JY3pQaDJKSVFDM1QtZDJrcF9aZWhSMm9UMUtrT2NrM25LR0VjZDNrS091TlZkSzZnbHhoNDJrWkI3bXdBZGdReEhfWFVJUjRSSGRUbERvTFlodlo2UEFmaXpsRGtQYmFiWUhqc0o2VXZ3WHo4VXRJZGg1c19EZXJjVkJGa0NmSHFMcUUtU0cxOXpodk1UdHVHcVhQRjVYZ2JLYUxpVWVrZlBYUkV4Q2pIOA?oc=5","date":"2026-03-26","type":"regulatory","source":"Stock Titan","summary":"Insight Molecular Diagnostics (IMDX) files GraftAssureDx with FDA and reports 2025 loss - Stock Titan","headline":"Insight Molecular Diagnostics (IMDX) files GraftAssureDx with FDA and reports 2025 loss","sentiment":"neutral"},{"date":"2026-03-26","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMib0FVX3lxTE9sekJHZmdWVjBjRlBtamNIMFNtNHZLR2kyZmR5YURNU3hoOWhFUDdhaWtpWnljMWtfdWpUVWdBMHVPRWpYdEdwV1V3b2IxRlEtQjNvb2plLWxNZVAyYlNIc3NRY1Bqd2RaUzlla0JGcw?oc=5","date":"2026-03-16","type":"pipeline","source":"Fortune Business Insights","summary":"Exosomes Market Size, Industry Share, Forecast, 2034 - Fortune Business Insights","headline":"Exosomes Market Size, Industry Share, Forecast, 2034","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxNbnM0TnFhTVl3dWdqT0dlaE12X3NMajAxUUVzRTBBVXpnYnczSFlZTUxXM0ItUWVhYWw2anA5WnB1bXV3bWdPaG5MR25CS290dDhLc3lfWG50aGVoS25lQ2o2VDZDczBOSFF3eDE0U0FKUFhEWVhtS0NMZ1ByRjdpZE9mN2d6bEc4N0tTemNpUQ?oc=5","date":"2026-03-13","type":"pipeline","source":"Yahoo Finance","summary":"How Insight Molecular Diagnostics (IMDX) Story Is Shifting With New Capital And GraftAssureDx Milestones - Yahoo Finance","headline":"How Insight Molecular Diagnostics (IMDX) Story Is Shifting With New Capital And GraftAssureDx Milestones","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggJBVV95cUxNYm9VMTdVdjFlU0hxQkFUT0VZVk1BSmI3YUtiWGZRcUFYT0t5TFEycE51aWJNbmRIRWpVX1RyUVZLT3JsYU5XWXJ3VG42QTRaVlFQWXhJdUVOUHNGbFJvQWNCYnNpcGN4UGh2c2VMU0g0ZmNybVkyQzMxNXl3aXdUb2QwT2hKUkRYUmZjS3ZkaHg0eWZTY1BYN1htcVQzeFVXVXMtOXF0dlMyZURJVXpwV21VSUE4c2FURVRraWNMaXNWNlBpVlE4RmxfTUZHLWpZbWZmbTMyNDZxOFlOMS1hRC1QRnJpXzR1VVR3RjQxcmhnVmg2TWx2VHFSQlRlanlIaHc?oc=5","date":"2026-03-03","type":"regulatory","source":"GlobeNewswire","summary":"Insight Molecular Diagnostics Completes Key Milestones Advancing GraftAssureDx Toward FDA Submission - GlobeNewswire","headline":"Insight Molecular Diagnostics Completes Key Milestones Advancing GraftAssureDx Toward FDA Submission","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxNMFNOcmlZVVpGS0Z4SVRTUWcyRDNhcl9rNE9GNjZLLU1Jemg4eExVNXk3ajBDZzlKenFCRk1CME9Sdjc1VWpBYzh0UWJwT2h6MmxieGI5MHNpT0NIMXVBQUc4djFlUXpkSUJ1LTJvTjhvVU5yWTg2Wk9VOC1VVDlpZXltSmJOa1ExNG1Db0Z4Yw?oc=5","date":"2026-02-27","type":"pipeline","source":"Yahoo Finance","summary":"How Insight Molecular Diagnostics (IMDX) Story Is Shifting With New Funding And GraftAssureDx Catalyst - Yahoo Finance","headline":"How Insight Molecular Diagnostics (IMDX) Story Is Shifting With New Funding And GraftAssureDx Catalyst","sentiment":"neutral"},{"date":"2026-02-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-11","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-12-23","type":"pipeline","source":"simplywall.st","summary":"Hedge funds investors control 50% of Insight Molecular Diagnostics Inc. (NASDAQ:IMDX) and were rewarded last week after stock increased 11% - simplywall.st","headline":"Hedge funds investors control 50% of Insight Molecular Diagnostics Inc. (NASDAQ:IMDX) and were rewarded last week after ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxQY2FsbEF0NExmMHdTNlNEN3pKNVpWNnNITG4zT2M4NldJT0pWUlB0dnN1U2FVa01tazVyTkN0YzZnTDFmdHduTThvcDFNNG5CaGczU2RPcS04cVpLUHpaV2o5ZU4ycVg5X1hoMmZBbmtuVHBmaDc1aEpLMkYxUmVOVEI1LUdtVXZ6VmwwLU5CeG5tWlVQR1phNlRBTGQ1VVZZdnlYd3Z5U1prQ2JQNk5mX1Y5dnpPejFVOTdKag?oc=5","date":"2025-11-14","type":"regulatory","source":"Seeking Alpha","summary":"Insight Molecular Diagnostics: GraftAssureDX FDA Submission Warrants Hold Rating (IMDX) - Seeking Alpha","headline":"Insight Molecular Diagnostics: GraftAssureDX FDA Submission Warrants Hold Rating (IMDX)","sentiment":"neutral"},{"date":"2025-11-10","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"discontinued":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar","revenue":4055000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":4055000,"period":"2025-12-31"},{"value":1881000,"period":"2024-12-31"},{"value":1881000,"period":"2024-12-31"},{"value":1503000,"period":"2023-12-31"},{"value":1503000,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":15900000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-50222000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":25756000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}